Literature DB >> 28082722

Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.

Wenhua Gao1, Wei Li2,3, Tengfei Xiao1,2,3, Xiaole Shirley Liu2,3, William G Kaelin4,5.   

Abstract

Most clear cell renal carcinomas (ccRCCs) are initiated by somatic inactivation of the VHL tumor suppressor gene. The VHL gene product, pVHL, is the substrate recognition unit of an ubiquitin ligase that targets the HIF transcription factor for proteasomal degradation; inappropriate expression of HIF target genes drives renal carcinogenesis. Loss of pVHL is not sufficient, however, to cause ccRCC. Additional cooperating genetic events, including intragenic mutations and copy number alterations, are required. Common examples of the former are loss-of-function mutations of the PBRM1 and BAP1 tumor suppressor genes, which occur in a mutually exclusive manner in ccRCC and define biologically distinct subsets of ccRCC. PBRM1 encodes the Polybromo- and BRG1-associated factors-containing complex (PBAF) chromatin remodeling complex component BRG1-associated factor 180 (BAF180). Here we identified ccRCC lines whose ability to proliferate in vitro and in vivo is sensitive to wild-type BAF180, but not a tumor-associated BAF180 mutant. Biochemical and functional studies linked growth suppression by BAF180 to its ability to form a canonical PBAF complex containing BRG1 that dampens the HIF transcriptional signature.

Entities:  

Keywords:  BAF180; PBAF; chromatin; hypoxia; kidney cancer

Mesh:

Substances:

Year:  2017        PMID: 28082722      PMCID: PMC5293026          DOI: 10.1073/pnas.1619726114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Kinetic analysis of acetylation-dependent Pb1 bromodomain-histone interactions.

Authors:  Christopher Kupitz; Renu Chandrasekaran; Martin Thompson
Journal:  Biophys Chem       Date:  2008-04-04       Impact factor: 2.352

2.  Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Andre P Fay; Guillermo de Velasco; Thai H Ho; Eliezer M Van Allen; Bradley Murray; Laurence Albiges; Sabina Signoretti; A Ari Hakimi; Melissa L Stanton; Joaquim Bellmunt; David F McDermott; Michael B Atkins; Levi A Garraway; David J Kwiatkowski; Toni K Choueiri
Journal:  J Natl Compr Canc Netw       Date:  2016-07       Impact factor: 11.908

Review 3.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

4.  Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma.

Authors:  Guangwu Guo; Yaoting Gui; Shengjie Gao; Aifa Tang; Xueda Hu; Yi Huang; Wenlong Jia; Zesong Li; Minghui He; Liang Sun; Pengfei Song; Xiaojuan Sun; Xiaokun Zhao; Sangming Yang; Chaozhao Liang; Shengqing Wan; Fangjian Zhou; Chao Chen; Jialou Zhu; Xianxin Li; Minghan Jian; Liang Zhou; Rui Ye; Peide Huang; Jing Chen; Tao Jiang; Xiao Liu; Yong Wang; Jing Zou; Zhimao Jiang; Renhua Wu; Song Wu; Fan Fan; Zhongfu Zhang; Lin Liu; Ruilin Yang; Xingwang Liu; Haibo Wu; Weihua Yin; Xia Zhao; Yuchen Liu; Huanhuan Peng; Binghua Jiang; Qingxin Feng; Cailing Li; Jun Xie; Jingxiao Lu; Karsten Kristiansen; Yingrui Li; Xiuqing Zhang; Songgang Li; Jian Wang; Huanming Yang; Zhiming Cai; Jun Wang
Journal:  Nat Genet       Date:  2011-12-04       Impact factor: 38.330

Review 5.  The SWI/SNF complex and cancer.

Authors:  D Reisman; S Glaros; E A Thompson
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

6.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

7.  Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.

Authors:  Yuchen Jiao; Timothy M Pawlik; Robert A Anders; Florin M Selaru; Mirte M Streppel; Donald J Lucas; Noushin Niknafs; Violeta Beleva Guthrie; Anirban Maitra; Pedram Argani; G Johan A Offerhaus; Juan Carlos Roa; Lewis R Roberts; Gregory J Gores; Irinel Popescu; Sorin T Alexandrescu; Simona Dima; Matteo Fassan; Michele Simbolo; Andrea Mafficini; Paola Capelli; Rita T Lawlor; Andrea Ruzzenente; Alfredo Guglielmi; Giampaolo Tortora; Filippo de Braud; Aldo Scarpa; William Jarnagin; David Klimstra; Rachel Karchin; Victor E Velculescu; Ralph H Hruban; Bert Vogelstein; Kenneth W Kinzler; Nickolas Papadopoulos; Laura D Wood
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

8.  BAP1 loss defines a new class of renal cell carcinoma.

Authors:  Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

9.  The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.

Authors:  Alexander Sankin; Abraham A Hakimi; Nina Mikkilineni; Irina Ostrovnaya; Mikhail T Silk; Yupu Liang; Roy Mano; Michael Chevinsky; Robert J Motzer; Stephen B Solomon; Emily H Cheng; Jeremy C Durack; Jonathan A Coleman; Paul Russo; James J Hsieh
Journal:  Cancer Med       Date:  2014-08-14       Impact factor: 4.452

Review 10.  Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics.

Authors:  Cigall Kadoch; Gerald R Crabtree
Journal:  Sci Adv       Date:  2015-06-12       Impact factor: 14.136

View more
  47 in total

1.  Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.

Authors:  A Ari Hakimi; Martin H Voss; Fengshen Kuo; Alejandro Sanchez; Ming Liu; Briana G Nixon; Lynda Vuong; Irina Ostrovnaya; Ying-Bei Chen; Victor Reuter; Nadeem Riaz; Yuan Cheng; Parul Patel; Mahtab Marker; Albert Reising; Ming O Li; Timothy A Chan; Robert J Motzer
Journal:  Cancer Discov       Date:  2019-01-08       Impact factor: 39.397

2.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Authors:  Diana Miao; Claire A Margolis; Wenhua Gao; Martin H Voss; Wei Li; Dylan J Martini; Craig Norton; Dominick Bossé; Stephanie M Wankowicz; Dana Cullen; Christine Horak; Megan Wind-Rotolo; Adam Tracy; Marios Giannakis; Frank Stephen Hodi; Charles G Drake; Mark W Ball; Mohamad E Allaf; Alexandra Snyder; Matthew D Hellmann; Thai Ho; Robert J Motzer; Sabina Signoretti; William G Kaelin; Toni K Choueiri; Eliezer M Van Allen
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

3.  Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis.

Authors:  Hye-Young Nam; Darshan S Chandrashekar; Anirban Kundu; Sandeep Shelar; Eun-Young Kho; Guru Sonpavde; Gurudatta Naik; Pooja Ghatalia; Carolina B Livi; Sooryanarayana Varambally; Sunil Sudarshan
Journal:  Mol Cancer Res       Date:  2018-08-21       Impact factor: 5.852

4.  PBRM1 bromodomains variably influence nucleosome interactions and cellular function.

Authors:  Mariesa J Slaughter; Erin K Shanle; Andrew W McFadden; Emily S Hollis; Lindsey E Suttle; Brian D Strahl; Ian J Davis
Journal:  J Biol Chem       Date:  2018-07-09       Impact factor: 5.157

5.  Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.

Authors:  Sabina Signoretti; Catherine J Wu; Sachet A Shukla; Toni K Choueiri; David A Braun; Yue Hou; Ziad Bakouny; Miriam Ficial; Miriam Sant' Angelo; Juliet Forman; Petra Ross-Macdonald; Ashton C Berger; Opeyemi A Jegede; Liudmilla Elagina; John Steinharter; Maxine Sun; Megan Wind-Rotolo; Jean-Christophe Pignon; Andrew D Cherniack; Lee Lichtenstein; Donna Neuberg; Paul Catalano; Gordon J Freeman; Arlene H Sharpe; David F McDermott; Eliezer M Van Allen
Journal:  Nat Med       Date:  2020-05-29       Impact factor: 53.440

6.  SWI/SNF tumor suppressor gene PBRM1/BAF180 in human clear cell kidney cancer.

Authors:  Amrita M Nargund; Hatice U Osmanbeyoglu; Emily H Cheng; James J Hsieh
Journal:  Mol Cell Oncol       Date:  2017-06-19

7.  A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells.

Authors:  Kejia Huang; Rong Sun; Jiarong Chen; Qianye Yang; Yucheng Wang; Yang Zhang; Kun Xie; Tiantian Zhang; Rui Li; Qi Zhao; Liang Zou; Jian Li
Journal:  Cell Cycle       Date:  2020-02-24       Impact factor: 4.534

Review 8.  Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma.

Authors:  Lynda Vuong; Ritesh R Kotecha; Martin H Voss; A Ari Hakimi
Journal:  Cancer Discov       Date:  2019-09-16       Impact factor: 39.397

9.  Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.

Authors:  Robert J Motzer; Romain Banchereau; Habib Hamidi; Thomas Powles; David McDermott; Michael B Atkins; Bernard Escudier; Li-Fen Liu; Ning Leng; Alexander R Abbas; Jinzhen Fan; Hartmut Koeppen; Jennifer Lin; Susheela Carroll; Kenji Hashimoto; Sanjeev Mariathasan; Marjorie Green; Darren Tayama; Priti S Hegde; Christina Schiff; Mahrukh A Huseni; Brian Rini
Journal:  Cancer Cell       Date:  2020-11-05       Impact factor: 31.743

Review 10.  Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers.

Authors:  Sabina Signoretti; Abdallah Flaifel; Ying-Bei Chen; Victor E Reuter
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.